The maintenance of a Buy rating by Maxim Group, despite the reduction in price target, suggests confidence in Quoin Pharmaceuticals' long-term potential. The significant upside potential indicated by the new price target could attract investor interest, potentially driving up the stock price in the short term. However, the substantial cut in the price target might also raise concerns about near-term challenges or revised expectations for the company's growth trajectory.